<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01653444</url>
  </required_header>
  <id_info>
    <org_study_id>GC1119_P1</org_study_id>
    <nct_id>NCT01653444</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Exploratory Efficacy of GC1119</brief_title>
  <official_title>Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119
      (recombinant human α-galactosidase A) for enzyme replacement therapy in Fabry disease
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>10weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change and %change of Plasma GL-3 concentration</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects whose plasma GL-3 values are within reference range</measure>
    <time_frame>10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of urine GL-3 concentration</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of kidney function</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of kidney size</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of heart size</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of results of cornial opacity examination</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of scores that are measured by pain questionnaire</measure>
    <time_frame>baseline and 10weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human α-galactosidase A</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1119, 0.5mg/kg</intervention_name>
    <description>biweekly, 0.5mg/kg IV infusion</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1119, 1.0mg/kg</intervention_name>
    <description>biweekly, 1.0mg/kg IV infusion</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a current diagnosis of Fabry's disease

          -  Plasma α-gal activity of ≤ 1.5mnol/hr/ml and have a mutation in α-galactosidase A
             gene

          -  Males ≥ 16 years old

          -  Subjects capable of performing this clinical trial in an appropriate manner

          -  Informed consent form voluntarily signed by the subject(or his legally acceptable
             representative if the subject is under 20 years old) to participation in the study

          -  Agreement to contraception during the study period

        Exclusion Criteria:

          -  Serum creatinine &gt; 2.5mg/dl

          -  Subjects have a plan to kidney transplantation

          -  Subjects have undergone kidney transplantation

          -  Subjects are currently on dialysis

          -  Subjects have a clinically significant organic disease(cardiovascular, hepatic,
             pulmonary, neurologic, or renal disease)that in the opinion of the investigator would
             preclude participation in the trial

          -  Known life-threatening hypersensitivity(anaphylactic reaction) to α-galactosidase

          -  Treatment with another investigational product within 30days from the administration
             of study drug dosing or plans to be treated with another investigational product
             during the study period

          -  Known hypersensitivity to any of the ingredients of study drug(including excipients)

          -  Subjects need the medication of prohibited drug

          -  Alcoholism or drug addiction
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Han Wook Yoo, M.D., Ph.D.</last_name>
    <phone>82-2-3010-3374</phone>
    <email>hwyoo@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Wook Yoo, M.D., Ph.D.</last_name>
      <phone>82-2-3010-3374</phone>
      <email>hwyoo@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Han Wook Yoo, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Cung Hyang University Hospital</name>
      <address>
        <city>Yongsan-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Hwan Lee, M.D., Ph.D.</last_name>
      <phone>82-2-709-9341</phone>
      <email>ldh@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong Hwan Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Yeongtong-gu</city>
        <state>Suwon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young Bae Sohn, M.D.</last_name>
      <phone>82-31-219-4447</phone>
      <email>ybsohn@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Bae Sohn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>July 30, 2012</lastchanged_date>
  <firstreceived_date>July 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
